Villere ST Denis J & Co. LLC Sells 9,440 Shares of Teleflex Incorporated (NYSE:TFX)

Villere ST Denis J & Co. LLC decreased its holdings in Teleflex Incorporated (NYSE:TFX - Free Report) by 5.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 168,276 shares of the medical technology company's stock after selling 9,440 shares during the period. Teleflex accounts for about 3.5% of Villere ST Denis J & Co. LLC's portfolio, making the stock its 6th biggest holding. Villere ST Denis J & Co. LLC owned approximately 0.36% of Teleflex worth $41,958,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in TFX. Commonwealth Equity Services LLC boosted its stake in Teleflex by 0.9% during the first quarter. Commonwealth Equity Services LLC now owns 4,688 shares of the medical technology company's stock valued at $1,187,000 after buying an additional 42 shares during the last quarter. Venturi Wealth Management LLC boosted its stake in Teleflex by 33.3% during the fourth quarter. Venturi Wealth Management LLC now owns 184 shares of the medical technology company's stock valued at $46,000 after buying an additional 46 shares during the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in Teleflex by 3.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 1,411 shares of the medical technology company's stock valued at $284,000 after buying an additional 48 shares during the last quarter. First Horizon Advisors Inc. boosted its stake in Teleflex by 39.1% during the first quarter. First Horizon Advisors Inc. now owns 178 shares of the medical technology company's stock valued at $45,000 after buying an additional 50 shares during the last quarter. Finally, Huntington National Bank boosted its stake in Teleflex by 26.5% during the third quarter. Huntington National Bank now owns 253 shares of the medical technology company's stock valued at $50,000 after buying an additional 53 shares during the last quarter. Institutional investors own 95.62% of the company's stock.

Teleflex Trading Up 0.1 %

Shares of NYSE TFX traded up $0.13 during midday trading on Monday, hitting $216.90. The company's stock had a trading volume of 244,330 shares, compared to its average volume of 264,200. The business's 50 day moving average is $232.38 and its two-hundred day moving average is $224.55. The firm has a market cap of $10.22 billion, a P/E ratio of 28.92, a price-to-earnings-growth ratio of 2.08 and a beta of 1.11. Teleflex Incorporated has a 12-month low of $177.63 and a 12-month high of $276.43. The company has a current ratio of 2.32, a quick ratio of 1.29 and a debt-to-equity ratio of 0.39.

Teleflex (NYSE:TFX - Get Free Report) last released its quarterly earnings data on Thursday, February 22nd. The medical technology company reported $3.38 EPS for the quarter, topping the consensus estimate of $3.26 by $0.12. The company had revenue of $773.90 million for the quarter, compared to the consensus estimate of $769.01 million. Teleflex had a return on equity of 14.98% and a net margin of 11.98%. Teleflex's quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the business posted $3.52 EPS. As a group, equities research analysts expect that Teleflex Incorporated will post 13.73 EPS for the current year.

Teleflex Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 15th. Shareholders of record on Friday, March 1st were issued a dividend of $0.34 per share. The ex-dividend date of this dividend was Thursday, February 29th. This represents a $1.36 annualized dividend and a yield of 0.63%. Teleflex's payout ratio is currently 18.06%.

Analyst Upgrades and Downgrades

TFX has been the subject of a number of research reports. JMP Securities reissued a "market outperform" rating and set a $285.00 price target on shares of Teleflex in a research note on Friday, February 23rd. Truist Financial lowered their price objective on Teleflex from $270.00 to $265.00 and set a "hold" rating for the company in a research note on Friday, February 23rd. StockNews.com lowered Teleflex from a "buy" rating to a "hold" rating in a research note on Friday, February 23rd. Raymond James raised their price objective on Teleflex from $227.00 to $271.00 and gave the company an "outperform" rating in a research note on Wednesday, December 20th. Finally, Royal Bank of Canada lowered their price objective on Teleflex from $272.00 to $265.00 and set an "outperform" rating for the company in a research note on Friday, February 23rd. Five investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $265.56.

Insiders Place Their Bets

In other Teleflex news, VP Cameron P. Hicks sold 7,401 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $225.00, for a total transaction of $1,665,225.00. Following the sale, the vice president now owns 10,050 shares of the company's stock, valued at approximately $2,261,250. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.41% of the stock is currently owned by company insiders.

Teleflex Profile

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.